GlassScriptPhysician profile
Harry David Harper
NPI 1811958481
$225,800.16
in general payments reported to CMS, 2019-2025
62 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $33K · 2021: $32K · 2022: $44K · 2023: $39K · 2024: $38K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Consulting Fee: $13K · Food and Beverage: $6,697 · Travel and Lodging: $4,093 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,842.00 |
| Consulting Fee | $12,606.25 |
| Food and Beverage | $6,697.27 |
| Travel and Lodging | $4,092.54 |
| Education | $200.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $156,080.59 | 2019-2025 | Opdivo, Augtyro |
| Astrazeneca Pharmaceuticals LP | $43,951.45 | 2019-2025 | Tagrisso, Imfinzi, Evusheld |
| Regeneron Healthcare Solutions, INC. | $7,343.11 | 2021-2025 | Libtayo |
| Pfizer INC. | $5,822.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,008.54 | 2021-2025 | Alunbrig, Vpriv |
| Daiichi Sankyo INC. | $1,041.26 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Celgene Corporation | $656.86 | 2019-2023 | |
| Amgen INC. | $639.63 | 2020-2023 | Lumakras, Xgeva, Nplate |
| Merck Sharp & Dohme LLC | $619.71 | 2019-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $587.33 | 2019-2025 | |
| Abbvie INC. | $353.57 | 2020-2025 | |
| Janssen Biotech, INC. | $333.64 | 2019-2025 | Rybrevant, Erleada |
| Jazz Pharmaceuticals INC. | $313.62 | 2020-2025 | |
| Astellas Pharma US INC | $237.62 | 2019-2024 | Xtandi |
Show all 61 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.